Educational paper: the effect of cancer therapy on fertility, the assessment of fertility and fertility preservation options for pediatric patients.
Over the past several decades, pediatric oncologists have seen the growth in the number of patients surviving their cancer. This is in large part due to the use of multimodal therapy including chemotherapy, surgery, and radiotherapy. As the number of survivors of pediatric cancer continues to grow, however, we need to begin to focus on improving the quality of the lives that are being saved. Unfortunately, many regimens used today to cure pediatric cancer patients are gonadotoxic. Therefore, many of our survivors must contend with infertility. It is critical that pediatric oncologists consider the likelihood of gonadotoxicity prior to beginning therapy in this patient population in order to counsel patients and their families properly in order to potentially offer fertility preservation options.


CONCLUSIONS
Infertility is a critical quality of life issue for pediatric cancer survivors and their families. Fertility preservation techniques need to continue to be studied and developed in order to lessen the likelihood that future cancer survivors will be infertile. This review outlines the risk for infertility, provides an assessment of the survivors reproductive functioning, and summarizes the currently available methods of preserving fertility in pediatric cancer survivors.
Division of Oncology, Center for Childhood Cancer Research, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. ginsbergji@email.chop.edu
Jill P
JP
Ginsberg
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D005298:Fertility / Q000187:drug effects* / Q000528:radiation effects*; D006801:Humans; D007246:Infertility / Q000209:etiology* / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D017410:Practice Guidelines as Topic; D011878:Radiotherapy / Q000009:adverse effects*; D012307:Risk Factors; D017741:Survivors
D000970:Antineoplastic Agents